Parents of man who died in Colorado jail say nurses, deputies ignored his pleas for 15 hours
The lawsuit blames them, local government officials and Southern Health Partners for failing to stop the death of Daniel Foard in 2023 by taking him to the hospital. Foard, 32, was a cook at a brewpub and user of fentanyl who was arrested for failing to appear in court. After being segregated and monitored for withdrawal from the synthetic opioid, he began vomiting and complained of stomach pain after being put in a regular jail cell, it said.
The lawsuit alleges Southern Health Partners — the Tennessee-based company they contracted with to provide health care at the La Plata County jail — has tried to maximize its profits at the jail by only having one nurse on duty at a time, leaving it to medically untrained deputies to monitor sick inmates. The company holds hundred of contracts at jails around the country and the lawsuit alleges that is has been involved in lawsuits related to the deaths of at least five other jail inmates nationally.
The company's lawyer, Shira Crittendon, said she had not seen the lawsuit and declined to comment on it.
The sheriff's office referred questions about the the lawsuit to a county spokesperson. In a statement, the county said it had not analyzed the allegations in the lawsuit and does not comment publicly on active litigation.
Autopsy found Foard died because of an ulcer
Foard was found dead in the jail on Aug. 17, 2023, six days after he was arrested.
An autopsy found Foard died as a result of a hole created by an ulcer in his small intestine, which caused inflammation of the tissue lining his abdomen. Such ulcers can let food and digestive juices leak out of the body's digestive tract.
Fentanyl, a synthetic opioid, was found in Foard's blood but the autopsy report did not name that as a cause of his death. Dr. Michael Arnall ruled Foard's death was due to natural causes.
On Aug. 15, 2023, even though Foard had collapsed several times and had trouble standing, he was moved out of an area where he could be more easily observed for problems with his withdrawal and put into a regular jail cell, staggering as we went, the lawsuit said. The day nurse ignored a deputy's concern that he was very unstable, according to the lawsuit brought by lawyers Dan Weiss, Anna Holland Edwards, John Holland and Erica Grossman.
After a deputy delivering breakfast on Aug. 16, 2023 saw that Foard repeatedly fell while trying to get his tray, the jail's day nurse came to check on him, it said. She recorded that Foard reported he had sharp, shooting pain that was a '10' on a scale of one to 10, but she did not call for a doctor or send him to the hospital, it said.
The nurse moved Foard to an empty cell where he could be monitored but didn't tell deputies what he was being monitored for and didn't order any follow up care or check on him, it said. He vomited all day and was moved to another cell and then a third because they had all become so messy with vomit, it said. Surveillance video showed him crawling to the final cell, where it said he continuously called out for help and yelled that he needed to go to a hospital, saying he was vomiting blood. The lawsuit claims that no one responded to his pleas but one deputy could be heard on surveillance video telling him to 'try to hit that drain' with his vomit to keep the cell from becoming dirty.
Another nurse, working the evening shift, only walked by his cell and glanced inside, but did not assess him or provide care as he was pleading for help, the lawsuit said. When she did enter his cell around 10 p.m., Foard was dead, it said. She told state investigators that vomiting was normal for people withdrawing from fentanyl.
State authorities investigated Foard's death
The day shift nurse later told a state investigator that it was not unusual that Foard would not have had his vital signs checked for 12 hours because of the number of inmates the jail's nurses need to provide care, according to a report from an investigation by the Colorado Bureau of Investigations. She also said she didn't think there was anything different she could have done based on Foard's symptoms.
The bureau's findings were forwarded to the 6th District Attorney's Office, which would decide whether any criminal charges were warranted in connection with Foard's death. It's not known whether the office decided to pursue any charges. A telephone message and email sent to District Attorney Sean Murray were not immediately returned.
In a statement, Jim Foard and Susan Gizinski said they want everyone to know about their son's ordeal both to hold those they say are responsible for his death accountable and to change how inmates are treated at the jail.
'Just basic training in having compassion for others would be a great start. But adding more staff is critical too,' they said.
Colleen Slevin, The Associated Press
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Wall Street Reacts: Lilly's Weight-Loss Pill Falls Short--But a New Obesity Drug War Just Began
Eli Lilly's (NYSE:LLY) next big bet on obesityan experimental pill called orforglipronjust returned late-stage trial data. The results? A solid 11% average weight loss over 18 months, or roughly 25 pounds. But it wasn't enough to impress Wall Street. Investors had been hoping for Wegovy-level numbers (1415%), and Lilly came in light. Shares dropped more than 12% in premarket trading Thursday. Meanwhile, rival Novo Nordisk (NYSE:NVO), the maker of Wegovy and Rybelsus, surged over 8% in Copenhagenits best intraday jump in months. Warning! GuruFocus has detected 4 Warning Sign with UAL. Still, the bigger picture might not be so bearish. Pills like orforglipron could play a critical role in making obesity drugs more accessible, especially as the market heads toward an estimated $95 billion by 2030. Unlike injectables, orforglipron is easier to make, potentially cheaper, and has a side-effect profile in line with existing GLP-1smainly nausea, vomiting, and diarrhea. About 10% of patients dropped out, but importantly, there were no signs of liver issues, which have plagued some oral rivals. Obesity specialists say effectiveness alone won't be the only driversafe, easy-to-use options matter just as much. Lilly says it will file for approval by the end of 2025, with hopes of hitting the market shortly after. The company is already stockpiling ingredients and has parked over $600 million worth of orforglipron-related inventory. The move suggests management is betting big despite the modest headline number. On the other side, Novo is gearing up for a decision on a higher-dose version of its Rybelsus pill after working through semaglutide production constraints. If both pills make it to shelves, they could open up a new front in the obesity drug warone focused not just on efficacy, but price, convenience, and scale. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 minutes ago
- Yahoo
Insulet beats second-quarter profit estimates on strong demand for insulin pumps
(Reuters) -Medical device maker Insulet beat Wall Street estimates for second-quarter profit and revenue on strong demand for its wearable insulin pumps, sending its shares up nearly 10% in premarket trading on Thursday. Insulet has been benefiting from the expanded approval for its automated insulin delivery device, Omnipod, which offers a convenient alternative to conventional pumps with external tubing by eliminating the need for multiple daily injections for people with insulin-dependent diabetes. Its Omnipod 5 device was cleared for use in both type 1 and type 2 diabetes patients last year. The company now expects its annual revenue to grow in the range of 24% to 27% from a year earlier, compared with its previous projection of 19% to 22%, betting on strong demand for Omnipod 5. The results suggest "Insulet's momentum is not only continuing, but accelerating", Baird analyst Jeff Johnson said. The company projects annual Omnipod revenue growth of 25% to 28%, up from a 20% to 23% growth forecast previously. Its Omnipod devices brought in sales of $639 million in the second quarter, above analysts' estimate of $606.15 million, according to data compiled by LSEG. On an adjusted basis, the company earned $1.17 per share, beating estimates of 93 cents. Total revenue jumped 33% to $649.1 million for the quarter ended June 30, compared with estimates of $612.22 million.
CNN
14 minutes ago
- CNN
‘SuperAgers' are blessed with a different brain, according to 25 years of research
The human brain shrinks as it ages, affecting the ability to remember — it's part of life. Yet there are a lucky few, called 'SuperAgers,' who possess a brain that fights back. For these people, memories stay as sharp as they were 30 or more years in the past. Carol Siegler, who lives in the Chicago suburb of Palatine, is a SuperAger. At 82, she won the American Crossword Puzzle Tournament for her age group, which she said she entered 'as a gag.' 'I've auditioned twice for 'Jeopardy!' and did well enough on it to be invited to the live auditions. Then Covid hit,' Siegler told me in 2022, when she was 85. Today, Siegler is still going strong, well on her way to her 90th birthday, said Tamar Gefen, an associate professor of psychiatry and behavioral sciences at the Mesulam Institute for Cognitive Neurology and Alzheimer's Disease at Northwestern University in Chicago. Gefen conducts research at Northwestern's SuperAging Program, which is currently studying 113 SuperAgers. Over the past 25 years, however, 80 SuperAgers have donated their brain tissue to the program, which has led to some fascinating discoveries. CNN spoke to Gefen about those decades of work. She is a coauthor of a new analysis of the research that was published Thursday in Alzheimer's & Dementia, the journal of the Alzheimer's Association. This interview has been lightly edited and condensed for clarity. CNN: How do you define a SuperAger, and what have you found out about their behavior over the years? Tamar Gefen: To be a SuperAger in our program at Northwestern, a person must be over 80 and undergo extensive cognitive testing. Acceptance in the study only occurs if the person's episodic memory — the ability to recall everyday events and past personal history — is as good or better than cognitively normal people in their 50s and 60s. We have screened close to 2,000 individuals who think they may be a SuperAger and less than 10% meet the criteria. Over the past 25 years, we have studied about 300 SuperAgers — a number of whom have donated their brain for research. One key trait of SuperAgers is that they seem to be highly social people. They value connection and are often active in their communities. This is interesting because we know isolation is a risk factor for developing dementia, and so staying socially active is a known protective feature. Another common thread in all SuperAgers is a sense of autonomy, freedom and independence. They're making decisions and living their lives the way that they want to live. I feel very strongly that successful aging is not just about sociability. If a person feels trapped, tethered or burdened, especially in a vulnerable state like poor health or older age, I think it can encroach on their entire psychosocial being. But as far as healthy behaviors, SuperAgers run the gamut. We have SuperAgers with heart disease, diabetes, who aren't physically active, who don't eat any better than their similar age peers. There is one SuperAger who drinks four beers every night. He laughs and says, 'Maybe it's done me wrong, but I'll never know.' He doesn't have an identical twin to compare his behavior to, so would he have lived to 108 instead of 98? We don't know. CNN: Many of your most intriguing discoveries have come from studying donor brain tissue. What have you discovered about the memory center of the SuperAger brain? Gefen: Our studies have shown that an area of the brain that is responsible for attention, motivation, and cognitive engagement — known as the cingulate cortex — is thicker in SuperAgers, even compared with those of people in their 50s and 60s. In the hippocampus, the memory center of the brain, we found SuperAgers have three times fewer tau tangles when compared to their 'normal' peers. Abnormal formations of tau proteins are one of the key signs of Alzheimer's. In Alzheimer's disease, tau also targets the neurons of the primary neurons of the cholinergic system — which is responsible for sustaining our attention in daily life. But that doesn't happen in the brain of a SuperAger. Therefore, the cholinergic system appears to be stronger, and likely more plastic and flexible for reasons that we're not sure about. That's interesting, because I see SuperAgers as focused. They can pay close attention, engage and actively listen. How else could they recall 13 out of 15 random words after 30 minutes? I picture them engraving the words on their cortex with a chisel. SuperAger brains also have bigger, healthier cells in the entorhinal cortex, an area essential for memory and learning, that has direct connections to the hippocampus. The entorhinal cortex, by the way, is one of the first areas of the brain to get hit by Alzheimer's disease. In another study we examined every layer of cells within the entorhinal cortex of SuperAgers, and we painstakingly measured the size of the neurons. We found that in layer two, which is the layer that is most important for information transmission, SuperAgers had humongous, plump, intact, beautiful, gigantic entorhinal cortex neurons. It was an incredible finding, because their entorhinal neurons were even larger than those in individuals who are much younger, some even in their 30s. That told us there is a structural integrity component at play — like the architecture, the bones, the skeleton of the neuron itself is sturdier. We're expanding the studies of these neurons to understand their biochemical signatures, determine what makes them special, and see if these signatures are found in other types of neurons in the brain of SuperAgers. Are these same neurons particularly vulnerable in those with Alzheimer's disease, and if so, how and why? CNN: What have you learned from your research about how the brain of a SuperAger reacts to injury, disease and stress? Gefen: We're looking at the inflammatory system in the brain of SuperAgers, with the goal of understanding how the immune cells in their brain respond to disease and adapt to stress. Inflammation, once it crosses a certain threshold, is a major component of cell loss in Alzheimer's disease and nearly all other neurodegenerative diseases. Compared with the brain of same-age peers, SuperAgers have fewer activated microglia, the resident immune cells of the brain, in their white matter. White matter is the brain's super highway, transporting information from one part of the brain to another. Here's how it works: Microglia are activated because there is some kind of antigen or disease, typically something destructive in the brain. In some cases, however, microglia and other immune cells become hyperactive and go into overdrive, thus causing inflammation and possible damage. The brain of a SuperAger, however, has fewer activated microglia. In fact, the levels of microglia were on par with people in their 30s, 40s and 50s. That could mean there is less junk or disease in the brain of a SuperAger so the microglia have no need to be active. Or it could mean microglia are responding efficiently to in clearing out disease or toxins, and because they are more plastic and adaptable, the microglia are able to activate, respond and then calm down. All of this is fascinating — it may be that at the cellular level, the immune system of a SuperAger brain could be stronger or more adaptive, much like the layers of cells we found in the entorhinal cortex. CNN: Whether or not you were born with the right genes to protect your brain sounds like the luck of the draw. What does that mean for the future? Gefen: Genetics are tricky. It's not just whether you have a gene or not, it about how your internal and external environment works together to influence how a gene is 'turned on,' or expressed — some may be more highly expressed, some will have lower expression. This is the epigenetic part of the puzzle. There is a list of candidate genes that we are starting to study very carefully, these are genes that also have a role in aspects of longevity, senescence, cell repair and cognitive reserve to name a few. I'm excited about that, not only for the genetics that are heritable from parents, but also genetics at the cell level, that enable each neuron or immune cell to carry out its respective job within the brain. With the technology that's advancing so rapidly, I'm certain we're going to get to a point where prevention or modification at the genetic level will be part of the playbook. Clearly, there is not a one target resolution for Alzheimer's disease. I know we all want that one easy fix but it's just simply not going to happen. It's going to take many teams and many specialists to come together and create a kind of personalized cocktail for prevention or treatment. I think it's possible, but it's going to take time.
